论文部分内容阅读
由西医、中医角度总结腹腔粘连(peritoneal adhesion,PA)的发病机制,对活血通腑类方剂防治腹腔粘连(PA)进展的机制进行总结。通过对国内外文献的整理发现防治腹腔粘连的活血通腑类方剂包括:活血通腑方、丹参厚朴合剂、理气活血汤等,基于临床疗效和药理机制两个层面归纳梳理其治疗腹腔粘连的研究进展。并对近八年活血通腑类中药报道的有效组分进行概述。今后基础研究可以从临床中药复方的主要组成药物的关键组分着手,结合体内、外的机制研究,以期从更深层次、更全面地阐明活血通腑类方治疗腹腔粘连的相关机制;临床研究,应根据实际情况选择确切阳性药物为对照组,进行以双盲、随机、对照为原则的大样本、多中心的临床试验,规范中医药治疗术后腹腔粘连的临床试验研究更为规范、可靠、全面。
The pathogenesis of peritoneal adhesion (PA) is summarized from the perspectives of Western medicine and Chinese medicine, and the mechanism of Huoxue Tongfu prescription in preventing and treating peritoneal adhesions (PA) is summarized. Through the collation of domestic and foreign literature found that prevention and treatment of peritoneal adhesions Huoxue Tongfu class prescriptions include: Huoxue Tongfu Fang, Danshen Houpai mixture, Liqi Huoxue Tang, based on clinical efficacy and pharmacological mechanism of two aspects summarized the treatment of abdominal adhesions Research progress. In the last eight years, the effective components reported in traditional Chinese medicine of Huoxuetongfu were summarized. In the future, basic research can start from the key components of the main constituents of the clinical Chinese medicine compound prescription and combine with the in vitro and in vivo mechanisms to clarify the related mechanism of Huoxue Tongfu Decoction for the treatment of abdominal adhesions in a deeper and more comprehensive manner. Clinical research, Should be based on the actual situation to select the exact positive drug control group, double-blind, randomized, control principle of large sample, multi-center clinical trials, standardized Chinese medicine treatment of postoperative abdominal adhesions clinical trials more standardized, reliable, comprehensive.